Acumen Pharmaceuticals Inc (ABOS) - News Archive

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a biopharmaceutical company at the forefront of Alzheimer s disease (AD) treatment, recently announced an extension of its collaboration with Lonza, a leading global manufact...

: Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on Alzheimer s disease treatments, has initiated a Phase 1 study for its investigational drug, sabirnetug (ACU193). This article outline...

Unveiling New Insights: Acumen Pharmaceuticals Showcases Promising Data from the INTERCEPT-AD Study at AAIC 2024In a significant stride towards advancing Alzheimer s disease (AD) research and treatment, Acumen Pharmaceu...

In a collaborative and palpable effort to tackle the pervasive and debilitating effects of Alzheimer s Disease (AD), Acumen Pharmaceuticals and Lonza have signed an agreement to advance the production and clinical devel...

In a groundbreaking move within the field of Alzheimer s disease research, Acumen Pharmaceuticals is poised to unveil compelling insights, including fluid biomarker data, during an Emerging Science Session at the presti...

Exploring the Efficacy of Sabirnetug (ACU193) in Early Alzheimer s Disease: Insights from Phase 1 INTERCEPT-AD StudyAlzheimer s disease (AD) is a devastating neurodegenerative disorder affecting millions of individuals...